TABLE 62Progression-free survival with nilotinib in CML-CP

StudyDoseLength of follow-upImatinibn6 months (years)12 months (years)18 months (years)24 months (years)36 months (years)
Kantarjian et al. (2007)106400 mg b.i.d.? updateaImR/ImI3210.9250.840.730.640.575
NRbImINR0.950.910.84
ImRNR0.860.770.63
Kantarjian et al. (2007)106400 mg b.i.d.? updatecImR/ImI3210.9250.840.730.640.575

?, unclear; NR, not reported.

a

Length of follow-up.

b

Data extracted from the cost-effectiveness model provided by Novartis as part of its submission to NICE.

c

Data appear to relate to conference abstract presenting ‘2-year follow-up results’ (note also expanded enrolment); not clear to what ‘2-year’ refers – may well be maximum follow-up, as time-to-event outcomes are only given to 18 months;172 in Novartis submission, these data were referred to as ‘a minimum of 19 months [sic] follow up’ (p. 19).205

From: 2, Assessment of clinical effectiveness

Cover of Dasatinib and Nilotinib for Imatinib-Resistant or -Intolerant Chronic Myeloid Leukaemia: A Systematic Review and Economic Evaluation
Dasatinib and Nilotinib for Imatinib-Resistant or -Intolerant Chronic Myeloid Leukaemia: A Systematic Review and Economic Evaluation.
Health Technology Assessment, No. 16.22.
Rogers G, Hoyle M, Thompson Coon J, et al.
Southampton (UK): NIHR Journals Library; 2012 Apr.
© 2012, Crown Copyright.

Included under terms of UK Non-commercial Government License.

PubMed Health. A service of the National Library of Medicine, National Institutes of Health.